Navigation Links
Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
Date:6/1/2008

Greater Than 50% Response Rate and 100% Disease Control Rate Observed in

Patients with Medullary Thyroid Cancer

CHICAGO, June 1 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) reported encouraging new data from an ongoing phase 1 clinical trial of XL184, a novel small molecule inhibitor of MET, VEGFR2, and RET, in patients with advanced malignancies. The maximum tolerated dose (MTD) for XL184 has been determined to be 175 mg/day given orally daily. Based on initial signs of clinical activity in a number of patients with medullary thyroid cancer (MTC) during the dose-escalation phase, the trial has been expanded to treat an additional 20 patients with MTC at the MTD. Ravi Salgia, MD, PhD, Associate Professor of Medicine and Director of the Thoracic Oncology Research Program at the University of Chicago Medical Center, and a lead investigator in the trial, presented the data today in the Developmental Therapeutics: Molecular Therapeutics oral abstract session (Abstract #3522) at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO).

Sixty patients were evaluated for safety, pharmacokinetics, and tumor response as of the May 1, 2008 cutoff; further data also were provided for nine additional patients after the cutoff. Across all tumor types, 10 patients had partial responses as determined by RECIST criteria: 9 partial responses were observed in patients with MTC (5 confirmed), and 1 in a patient with a neuroendocrine tumor. An additional 25 patients with various tumor types had stable disease for at least 3 months, including 8 patients with MTC. The disease control rate (percentage of patients with partial responses or prolonged stable disease >3 months) in patients with MTC was
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
9. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
10. Exelixis Announces First Quarter 2008 Financial Results
11. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 The signing of ... and New Jersey Health Foundation (NJHF) to work ... care programs has been announced by Rodger ... Kessler Foundation and James M. Golubieski , ... "The experience of New Jersey Health Foundation in ...
(Date:9/30/2014)... NEWPORT BEACH, Calif. , Sept. 30, 2014 ... prestigious accreditation of the American Association of Tissue ... Russell Cook , Chief Executive Officer. ... on-site inspection by a specially trained AATB inspector.  ... and administrative performance within the facility meets or ...
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern European ... established medical-device providers as well as new medical-device manufacturers ... while simultaneously looking at ways to reduce the cost ... distributors is one of the effective means to achieve ... distribution market in Eastern European and provides profiles of ...
Breaking Medicine Technology:Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Biostructures, LLC Earns AATB Accreditation 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3
... SAN DIEGO, Dec. 5, 2011 ForteBio®, Inc., a ... of biotherapeutic and pharmaceutical products, today announced the launch ... scientists – for the first time – to conduct ... and cost-efficiently at their lab bench. The new platform ...
... Bupa International has published two new health guides for ... information on vaccinations, medical insurance and emergency healthcare. ... a growing number of people relocate to foreign countries ... region is particularly needed, as the area,s many booming ...
Cached Medicine Technology:ForteBio Introduces BLItz™, a Revolutionary, Micro-volume Label-free Analysis Platform for Personal Assays 2ForteBio Introduces BLItz™, a Revolutionary, Micro-volume Label-free Analysis Platform for Personal Assays 3Bupa International Releases Health Guides to Hong Kong and Singapore 2
(Date:9/30/2014)... to be proactive about potential disease outbreaks like Ebola ... In an Editorial in the October issue of ... Allen Cheng from Monash University and Heath Kelly from ... health crises. , "Australia would do well to heed ... in co-ordinating a consistent and outward looking response," the ...
(Date:9/30/2014)... By Dennis Thompson ... -- The first confirmed case of Ebola has surfaced in ... from Liberia, federal health officials announced late Tuesday. The ... Hospital in Dallas, has been diagnosed with the deadly ... Prevention said in a late afternoon news conference. The ...
(Date:9/30/2014)... climate-changing carbon emissions will reduce other harmful air ... to a new study released today. The research ... in the final Clean Power Plan, the power ... and hospitalizations, and hundreds of heart attacks in ... study, Health Co-benefits of Carbon Standards for Existing ...
(Date:9/30/2014)... Sleep apnea is a potential health risk for millions of ... behind the disorder: a "fat" tongue. "This is the ... the tongue of obese patients with obstructive sleep apnea," study ... at the University of Pennsylvania Medical Center, said in a ... findings Oct. 1. Sleep apnea is a common disorder ...
(Date:9/30/2014)... Keystone Symposia will convene the first conference of its ... Health Series on "The Modes of Action of ... following the conclusion of the Grand Challenges Meeting for ... the Keystone Symposia Global Health Series, supported by the ... travel awards for 36 investigators from developing countries to ...
Breaking Medicine News(10 mins):Health News:CDC Confirms First Patient Diagnosed With Ebola in United States 2Health News:CDC Confirms First Patient Diagnosed With Ebola in United States 3Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:Could a 'Fat Tongue' Be a Factor in Sleep Apnea? 2Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2
... on their way to office or back home, with the ... Manchester Piccadilly train stations//. This patient friendly system eliminates ... from 7 a.m. to 7 p.m. ,Such a ... for the request of the general public, demanding a quick ...
... effective anti-depressant is also found to interact with immune ... mechanism of serotonin inhibitors on human health//. ... Georgetown University Medical center have found that SSRI (Selective ... an effective antidepressant by passing between the neurons ...
... Researchers have identified an increased incidence of melanoma among the ... the March 1, 2006 issue// of CANCER, a peer-reviewed journal ... melanoma- an invasive form of skin cancer- is of the ... ,It is generally accepted that melanoma is by far ...
... who use vaginal washes run a higher risk of contracting HIV/AIDS.// ... led by Scott McClelland. The women who live in the sub-Saharan ... Kenyan women were examined during the course of the study. ... they washed with soap were four times more likely to be ...
... in the lymph nodes also, according to a recent research, ... mammalian immune response. // ,The dreaded disease ... mammal, and the immature parasites travel to the animal's liver. ... the liver cells and infect red blood cells, beginning the ...
... provided by researchers that faith healing and special diets also ... Melbourne led the research // which studied as many as ... served to extend the life of 25 people for a ... ,Dr Macmanus said that the data showed ...
Cached Medicine News:Health News:Invasive Skin Cancer On The Rise in Hispanics 2Health News:Malaria Can Develop In Lymph Nodes Also 2
... first fully automated blood ... North American market based ... Test™. The ORTHO ProVue™ ... while increasing productivity via ...
The ScanGel® automatic readings are done with a high resolution color video camera. Images can be stored and printed....
... are in need of MRI exams, many ... scanners. They have heard of, or experienced ... and noisy tubes of supercon scanners - ... people want is a patient-friendly MRI. Now ...
... early 1990s, the "Reversed" shoulder prosthesis has ... great success. More recently, an ever-growing number ... begun to champion this prosthesis and the ... This reversed technology is the result of ...
Medicine Products: